Citi’s 16th Annual BioPharma Conference on September 8, 2021
Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021 at 5:00 pm ET
2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021 at 1:20 pm ET
HC Wainwright 23rd Annual Global Investment Conference on September 13, 2021 at 7:00 am ET
SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines on September 23, 2021
2021 Cantor Virtual Global Healthcare Conference on September 27, 2021 at 8:00 am ET
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the following investor healthcare conferences: Citi’s 16th Annual BioPharma Conference, Morgan Stanley 19th Annual Global Healthcare Conference, 2021 Wells Fargo Virtual Healthcare Conference, HC Wainwright 23rd Annual Global Investment Conference and the 2021 Cantor Virtual Global Healthcare Conference and the SVB Leerink CybeRx Series.
Conferences Details:
Event: |
Citi’s 16th Annual BioPharma Conference |
|
Date: |
Wednesday September 8, 2021 |
|
Format: |
1x1 meetings |
|
Participants: |
RA Session II, President, Founder and CEO |
|
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D |
||
Kamran Alam, Chief Financial Officer |
||
Kimberly Lee, SVP, Corporate Communications and Investor Relations |
Event: |
Morgan Stanley 19th Annual Global Healthcare Conference |
|
Date: |
Thursday September 9, 2021 |
|
Time: |
5:00 pm ET |
|
Format: |
Fireside chat |
|
Participants: |
RA Session II, President, Founder and CEO |
|
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D |
||
Kamran Alam, Chief Financial Officer |
Event: |
2021 Wells Fargo Virtual Healthcare Conference |
|
Date: |
Friday September 10, 2021 |
|
Time: |
1:20 pm ET |
|
Format: |
Fireside chat |
|
Participants: |
RA Session II, President, Founder and CEO |
|
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D |
||
Kamran Alam, Chief Financial Officer |
Event: |
HC Wainwright 23rd Annual Global Investment Conference |
|
Date: |
Monday September 13, 2021 |
|
Time: |
7:00 am ET |
|
Format: |
Fireside chat |
|
Participants: |
RA Session II, President, Founder and CEO |
|
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D |
||
Kamran Alam, Chief Financial Officer |
Event: |
SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicine |
|
Date: |
Thursday September 23, 2021 |
|
Format: |
1x1 meetings |
|
Participants: |
RA Session II, President, Founder and CEO |
|
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D |
||
Kamran Alam, Chief Financial Officer |
||
Kimberly Lee, SVP, Corporate Communications and Investor Relations |
Event: |
2021 Cantor Virtual Global Healthcare Conference |
|
Date: |
Monday September 27, 2021 |
|
Time: |
8:00 am ET |
|
Format: |
Fireside Chat |
|
Participants: |
RA Session II, President, Founder and CEO |
|
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D |
||
Kamran Alam, Chief Financial Officer |
Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005994/en/
Contacts
Company Contact:
Kimberly Lee, D.O.
SVP, Corporate Communications and Investor Relations
Taysha Gene Therapies
klee@tayshagtx.com
Media Contact:
Carolyn Hawley
Canale Communications
carolyn.hawley@canalecomm.com
